Jatin Shah - May 7, 2021 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP, Chief Medical Officer
Signature
/s/ Nancy Smith as Attorney-in-Fact for Jatin Shah
Stock symbol
KPTI
Transactions as of
May 7, 2021
Transactions value $
$199,992
Form type
4
Date filed
5/11/2021, 08:58 AM
Next filing
Jul 13, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Purchase $200K +23.3K +21.42% $8.60* 132K May 7, 2021 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $8.5850 to $8.61, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F2 Includes 861 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on April 30, 2021.